

LYMPHOMA FOUNDATION OF AMERICA

FINANCIAL STATEMENTS
and
SUPPLEMENTARY INFORMATION
with
INDEPENDENT ACCOUNTANT'S
REVIEW REPORT

DECEMBER 31, 2024 AND 2023

LYMPHOMA FOUNDATION OF AMERICA

REVIEWED FINANCIAL STATEMENTS

For the Years Ended December 31, 2024 and 2023

CONTENTS

	<u>Page</u>
INDEPENDENT ACCOUNTANT'S REVIEW REPORT	1
FINANCIAL STATEMENTS	
STATEMENTS OF FINANCIAL POSITION	2
STATEMENTS OF ACTIVITIES	3
STATEMENTS OF CASH FLOWS	4
STATEMENT OF FUNCTIONAL EXPENSES – 2024	5
STATEMENT OF FUNCTIONAL EXPENSES - 2023	6
NOTES TO FINANCIAL STATEMENTS	7-10

Walter, Boesky & Associates, P.C.

Certified Public Accountants

17320 W. 12 Mile Road, Suite 200, Southfield, Michigan 48076-2105

248-559-4750

Fax 248-559-8008

INDEPENDENT ACCOUNTANT'S REVIEW REPORT

Board of Directors
Lymphoma Foundation of America

We have reviewed the accompanying financial statements of the Lymphoma Foundation of America (a nonprofit organization), which comprise the statement of financial position as of December 31, 2024 and 2023 and the related statement of activities, cash flows, and functional expenses for the years then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

Accountant's Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of Lymphoma Foundation of America and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our review.

Accountant's Conclusion

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

*Walter, Boesky &
Associates, P.C.*

Southfield, Michigan
November 17, 2025

LYMPHOMA FOUNDATION OF AMERICA

STATEMENTS OF FINANCIAL POSITION

Years Ended December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
ASSETS		
CURRENT ASSETS		
Checking accounts	\$ 57,831	\$ 50,272
Total Cash and Equivalents	57,831	50,272
Certificate of deposit	-	56,293
Government obligations	391,152	322,461
Total Investments	391,152	378,754
Total Current Assets	448,983	429,026
PROPERTY AND EQUIPMENT		
Property and equipment - at cost	1,803	1,803
Less accumulated depreciation and amortization	(1,803)	(1,803)
Total Property and Equipment	-	-
Total Assets	<u>\$ 448,983</u>	<u>\$ 429,026</u>
LIABILITIES		
CURRENT LIABILITIES		
Accrued expenses	\$ 16,800	\$ 271
Total Current Liabilities	16,800	271
NET ASSETS - Without Donor Restrictions	432,183	428,755
Total Liabilities and Net Assets	<u>\$ 448,983</u>	<u>\$ 429,026</u>

The accompanying notes and accountant's audit report
are an integral part of these financial statements.

LYMPHOMA FOUNDATION OF AMERICA

STATEMENTS OF ACTIVITIES

Years Ended December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
UNRESTRICTED NET ASSETS		
Revenue		
Contributions	\$ 64,180	\$ 64,136
Interest income	<u>15,577</u>	<u>18,659</u>
Total Revenue	79,757	82,795
Expenses		
Program services	75,171	87,416
Administrative services	<u>1,158</u>	<u>1,090</u>
Total Expenses	<u>76,329</u>	<u>88,506</u>
Increase (Decrease) in Net Assets	3,428	(5,711)
Net Assets - Beginning of Year	<u>428,755</u>	<u>434,466</u>
Net Assets - End of Year	<u>\$ 432,183</u>	<u>\$ 428,755</u>

The accompanying notes and accountant's audit report
are an integral part of these financial statements.

LYMPHOMA FOUNDATION OF AMERICA

STATEMENTS OF CASH FLOWS

Years Ended December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Income	\$ 3,428	\$ (5,711)
Adjustments to reconcile net income to net cash provided by operating activities:		
Decrease (increase) in operating assets		
Accounts payable	<u>16,529</u>	<u>(40)</u>
Net cash provided by operations	<u>19,957</u>	<u>(5,751)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of government obligations	(183,691)	(622,390)
Redemption of government obligations	115,000	640,000
Purchase of certificate of deposits	-	(1,525)
Redemption of certificate of deposits	<u>56,293</u>	<u>-</u>
Net cash used by investing activities	<u>(12,398)</u>	<u>16,085</u>
Net increase in cash and equivalents	7,559	10,334
Beginning cash and cash equivalents	<u>50,272</u>	<u>39,938</u>
Ending cash and cash equivalents	<u>\$ 57,831</u>	<u>\$ 50,272</u>

The accompanying notes and accountant's audit report
are an integral part of these financial statements.

LYMPHOMA FOUNDATION OF AMERICA

STATEMENT OF FUNCTIONAL EXPENSES

Year ended December 31, 2024

	Program Services	Administrative Services	Total
Education and outreach	\$ 2,099	\$ -	\$ 2,099
Counseling and support services	48,982	-	48,982
Research	21,322	-	21,322
Subtotal	<u>72,403</u>	<u>-</u>	<u>72,403</u>
Audit and tax preparation	1,926	949	2,875
Conferences and meetings	331	-	331
Occupancy	511	209	720
Office expense	<u>-</u>	<u>-</u>	<u>-</u>
	<u>\$ 75,171</u>	<u>\$ 1,158</u>	<u>\$ 76,329</u>

The accompanying notes and accountant's audit report are an integral part of these financial statements.

LYMPHOMA FOUNDATION OF AMERICA

STATEMENT OF FUNCTIONAL EXPENSES

Year ended December 31, 2023

	Program Services	Administrative Services	Total
Education and outreach	\$ 1,145	\$ -	\$ 1,145
Counseling and support services	55,703	-	55,703
Research	24,803	-	24,803
Subtotal	<u>81,651</u>	<u>-</u>	<u>81,651</u>
Audit and tax preparation	1,585	790	2,375
Conferences and meetings	3,326	-	3,326
Occupancy	720	300	1,020
Office expense	134	-	134
	<u>\$ 87,416</u>	<u>\$ 1,090</u>	<u>\$ 88,506</u>

The accompanying notes and accountant's audit report are an integral part of these financial statements.

Lymphoma Foundation of America
NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

NOTE A – NATURE OF OPERATIONS

The Lymphoma Foundation of America (the “Foundation”) is a national organization devoted solely to helping lymphoma patients and their families. The Foundation is an independent, non-profit charitable organization under the leadership of an appointed Board of Directors.

The Foundation is dedicated to helping people find the best care available for each specific type of lymphoma. It was founded in 1986 by people with lymphoma who came together to help each other recover from cancer.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The financial statements of the Foundation have been prepared in conformity with generally accepted accounting principles as applied to certain non-profit organizations.

A summary of the Foundation's significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.

1. Basis of Accounting

The records are maintained and these financial statements have been prepared using the accrual basis of accounting.

2. Cash Equivalents

Cash and cash equivalents are defined as highly liquid investments with maturity of three months or less at the date of purchase.

3. Furniture and Equipment

Property and equipment are carried at cost or, if donated, at market value at the date of donation. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets.

4. Contributions

Contributions are recorded at fair value when received and recognized as revenue concurrently.

5. Use of Estimates

The financial statements of the Foundation have been prepared in accordance with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.

Lymphoma Foundation of America
NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

6. Basis of Presentation

Net assets, revenues, gains and losses are classified based on the existence or absence of donor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions – Net assets available for use in general operations and not subject to donor restrictions.

Net Assets With Donor Restrictions – Net assets subject to donor imposed restrictions. Some donor imposed restrictions are temporary in nature, such as those that will be met by the passage of time or events specified by the donor. Other donor imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Donor imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

7. Investments

Investments in marketable securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the statement of financial position. Unrealized gains and losses are included in the change in net assets. Investment income and gains restricted by a donor are reported as increases in unrestricted net assets if the restrictions are met (either by passage of time or by use) in the reporting period in which the income and gains are recognized.

8. Subsequent Events

The Foundation has evaluated subsequent events through November 17, 2025, the date the financial statements were available to be issued.

NOTE C - INCOME TAXES

The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. The Foundation has obtained a favorable tax determination letter from the Internal Revenue Service, and the Board of Directors believes that the Foundation continues to qualify and to operate in accordance with applicable provisions of the Internal Revenue Code. Therefore, no provision for income taxes has been included in the Foundation's financial statements.

Accounting principles generally accepted in the United States of America require management to evaluate tax positions taken and recognize a tax liability (or asset) if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. The Foundation is subject to routine audits by taxing jurisdictions; however there are currently no audits for any tax periods in progress. The trustees believe it is no longer subject to tax examinations for years prior to 2021

Lymphoma Foundation of America

NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

NOTE D - INVESTMENTS

The Foundation's balance of investments during 2024 and 2023 were without donor restrictions. Investments that represent 5% or more of the Foundation's net assets are separately identified.

	<u>2024</u>	<u>2023</u>
Certificate of Deposits	\$ -0-	\$ 56,293
Government Obligations	<u>391,152</u>	<u>22,461</u>
Total	<u>\$ 391,152</u>	<u>\$ 378,754</u>

NOTE E – FAIR VALUE MEASUREMENTS

Financial Accounting Standards Board (FASB) *Accounting Standards Codification (ASC) 820, Fair Value Measurement and Disclosures*, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described below:

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Foundation has the ability to access.
- Level 2 Inputs to the valuation methodology include:
- Quote prices for similar assets or liabilities in active markets;
 - Quoted prices for identical or similar assets or liabilities in inactive markets;
 - Inputs other than quoted prices that are observable for the asset or liability;
 - Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Lymphoma Foundation of America
NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

NOTE E – FAIR VALUE MEASUREMENTS - Continued

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2024 and 2023.

Common stocks, corporate bonds and U.S. Government securities: Valued at the closing price reported in the active market in which the individual security is traded.

Certificate of Deposits: are valued at amortized cost plus accrued interest, which approximates fair value, and are classified as Level 1.

Investments Assets at Fair Value
as of December 31, 2024

	Level 1	Level 2	Level 3	Total
Investments				
Certificate of Deposits	\$ -	\$ -	\$ -	\$ -
Government Obligations	391,152	-	-	391,152
Total Investments at Fair Value:	<u>\$ 391,152</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 391,152</u>

Investments Assets at Fair Value
as of December 31, 2023

	Level 1	Level 2	Level 3	Total
Investments				
Certificate of Deposit	\$ -	\$ 56,293	\$ -	\$ 56,293
Government Obligations	322,461	-	-	322,461
Total Investments at Fair Value:	<u>\$ 322,461</u>	<u>\$ 56,293</u>	<u>\$ -</u>	<u>\$ 378,754</u>